Skip Nav Destination
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP
Twenty-five–year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL
Issue Archive
June 15 2008
In this Issue
Table of Contents
INSIDE BLOOD
ASH 50TH ANNIVERSARY REVIEW
PLENARY PAPERS
PERSPECTIVE
REVIEW ARTICLES
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
Michael Hallek,Bruce D. Cheson,Daniel Catovsky,Federico Caligaris-Cappio,Guillaume Dighiero,Hartmut Döhner,Peter Hillmen,Michael J. Keating,Emili Montserrat,Kanti R. Rai,Thomas J. Kipps
CHEMOKINES, CYTOKINES, AND INTERLEUKINS
CLINICAL TRIALS AND OBSERVATIONS
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study
Clinical Trials & Observations
Michael J. Borowitz,Meenakshi Devidas,Stephen P. Hunger,W. Paul Bowman,Andrew J. Carroll,William L. Carroll,Stephen Linda,Paul L. Martin,D. Jeanette Pullen,David Viswanatha,Cheryl L. Willman,Naomi Winick,Bruce M. Camitta,for the Children's Oncology Group13
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
Clinical Trials & Observations
Anton Hagenbeek,Ole Gadeberg,Peter Johnson,Lars Møller Pedersen,Jan Walewski,Andrzej Hellmann,Brian K. Link,Tadeusz Robak,Marek Wojtukiewicz,Michael Pfreundschuh,Michael Kneba,Andreas Engert,Pieter Sonneveld,Mimi Flensburg,Jørgen Petersen,Nedjad Losic,John Radford
ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
Clinical Trials & Observations
Kerry J. Savage,Nancy Lee Harris,Julie M. Vose,Fred Ullrich,Elaine S. Jaffe,Joseph M. Connors,Lisa Rimsza,Stefano A. Pileri,Mukesh Chhanabhai,Randy D. Gascoyne,James O. Armitage,Dennis D. Weisenburger,for the International Peripheral T-Cell Lymphoma Project
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP
Clinical Trials & Observations
Raquel Malumbres,Jun Chen,Rob Tibshirani,Nathalie A. Johnson,Laurie H. Sehn,Yaso Natkunam,Javier Briones,Ranjana Advani,Joseph M. Connors,Gerald E. Byrne,Ronald Levy,Randy D. Gascoyne,Izidore S. Lossos
Twenty-five–year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study
Clinical Trials & Observations
Rajen Mody,Suwen Li,Douglas C. Dover,Stephen Sallan,Wendy Leisenring,Kevin C. Oeffinger,Yutaka Yasui,Leslie L. Robison,Joseph P. Neglia
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
Clinical Trials & Observations
Issa F. Khouri,Peter McLaughlin,Rima M. Saliba,Chitra Hosing,Martin Korbling,Ming S. Lee,L. Jeffrey Medeiros,Luis Fayad,Felipe Samaniego,Amin Alousi,Paolo Anderlini,Daniel Couriel,Marcos de Lima,Sergio Giralt,Sattva S. Neelapu,Naoto T. Ueno,Barry I. Samuels,Fredrick Hagemeister,Larry W. Kwak,Richard E. Champlin
GENE THERAPY
HEMATOPOIESIS AND STEM CELLS
The combination of granulocyte colony-stimulating factor and stem cell factor significantly increases the number of bone marrow–derived endothelial cells in brains of mice following cerebral ischemia
Zsuzsanna E. Toth,Ronen R. Leker,Tal Shahar,Sandra Pastorino,Ildiko Szalayova,Brook Asemenew,Sharon Key,Alissa Parmelee,Balazs Mayer,Krisztian Nemeth,Andras Bratincsák,Éva Mezey
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Genotype-phenotype correlation in combined deficiency of factor V and factor VIII
Bin Zhang,Marta Spreafico,Chunlei Zheng,Angela Yang,Petra Platzer,Michael U. Callaghan,Zekai Avci,Namik Ozbek,Johnny Mahlangu,Tabitha Haw,Randal J. Kaufman,Kandice Marchant,Edward G. D. Tuddenham,Uri Seligsohn,Flora Peyvandi,David Ginsburg
IMMUNOBIOLOGY
NEOPLASIA
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders
Elizabeth O. Hexner,Cynthia Serdikoff,Mahfuza Jan,Cezary R. Swider,Candy Robinson,Shi Yang,Thelma Angeles,Stephen G. Emerson,Martin Carroll,Bruce Ruggeri,Pawel Dobrzanski
Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL
Brief Report
Dalemari Crowther-Swanepoel,Ruth Wild,Gabrielle Sellick,Martin J. S. Dyer,Francesca R. Mauro,Robert J. G. Cuthbert,Viggo Jonsson,Estella Matutes,Claire Dearden,James Wiley,Stephen Fuller,Daniel Catovsky,Richard S. Houlston
PHAGOCYTES
RED CELLS
Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease
Allison E. Ashley-Koch,Laine Elliott,Melanie E. Kail,Laura M. De Castro,Jude Jonassaint,Terry L. Jackson,Jennifer Price,Kenneth I. Ataga,Marc C. Levesque,J. Brice Weinberg,Eugene P. Orringer,Ann Collins,Jeffery M. Vance,Marilyn J. Telen
TRANSPLANTATION
Keratinocyte growth factor and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T-cell reconstitution after murine bone marrow transplantation
Ryan M. Kelly,Steven L. Highfill,Angela Panoskaltsis-Mortari,Patricia A. Taylor,Richard L. Boyd,Georg A. Holländer,Bruce R. Blazar
Neonatal bone marrow transplantation of ADA-deficient SCID mice results in immunologic reconstitution despite low levels of engraftment and an absence of selective donor T lymphoid expansion
Denise A. Carbonaro,Xiangyang Jin,Daniel Cotoi,Tiejuan Mi,Xiao-Jin Yu,Dianne C. Skelton,Frederick Dorey,Rodney E. Kellems,Michael R. Blackburn,Donald B. Kohn
CORRESPONDENCE
ERRATUM
-
Cover Image
Cover Image
![issue cover]()
The structure of the N-terminal region of alpha-spectrin. See the related article by Gaetani et al beginning on page 5712. They measure the effects of some common mutations associated with hereditary elliptocytosis, including residues I24, R28, and R45 in the first alpha-helix, which can entirely abolish interaction with beta-spectrin. The image was drawn from Protein Databank entry 1OWA (Park S, Caffrey MS, Johnson ME, Fung LW. Solution structural studies on human erythrocyte alpha-spectrin tetramerization site. J Biol Chem. 2003;278:21837-21844.) by Anthony Baines and Debra Tyler.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement
Email alerts
Advertisement
